Artiva Biotherapeutics (ARTV) Competitors $2.95 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.94 -0.01 (-0.17%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ARTV vs. TECX, LXEO, MREO, ABEO, CADL, DBVT, ALLO, EDIT, REPL, and LYELShould you be buying Artiva Biotherapeutics stock or one of its competitors? The main competitors of Artiva Biotherapeutics include Tectonic Therapeutic (TECX), Lexeo Therapeutics (LXEO), Mereo BioPharma Group (MREO), Abeona Therapeutics (ABEO), Candel Therapeutics (CADL), DBV Technologies (DBVT), Allogene Therapeutics (ALLO), Editas Medicine (EDIT), Replimune Group (REPL), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry. Artiva Biotherapeutics vs. Its Competitors Tectonic Therapeutic Lexeo Therapeutics Mereo BioPharma Group Abeona Therapeutics Candel Therapeutics DBV Technologies Allogene Therapeutics Editas Medicine Replimune Group Lyell Immunopharma Tectonic Therapeutic (NASDAQ:TECX) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Is TECX or ARTV more profitable? Tectonic Therapeutic's return on equity of -30.13% beat Artiva Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tectonic TherapeuticN/A -30.13% -28.33% Artiva Biotherapeutics N/A -42.60%-37.76% Which has higher earnings and valuation, TECX or ARTV? Tectonic Therapeutic has higher earnings, but lower revenue than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTectonic TherapeuticN/AN/A-$57.98M-$4.04-3.77Artiva Biotherapeutics$250K288.27-$65.37MN/AN/A Which has more volatility & risk, TECX or ARTV? Tectonic Therapeutic has a beta of 3.21, indicating that its share price is 221% more volatile than the S&P 500. Comparatively, Artiva Biotherapeutics has a beta of 2.83, indicating that its share price is 183% more volatile than the S&P 500. Does the media favor TECX or ARTV? In the previous week, Artiva Biotherapeutics had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 1 mentions for Artiva Biotherapeutics and 0 mentions for Tectonic Therapeutic. Artiva Biotherapeutics' average media sentiment score of 0.59 beat Tectonic Therapeutic's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Overall Sentiment Tectonic Therapeutic Neutral Artiva Biotherapeutics Positive Do insiders & institutionals believe in TECX or ARTV? 62.6% of Tectonic Therapeutic shares are held by institutional investors. 38.0% of Tectonic Therapeutic shares are held by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate TECX or ARTV? Tectonic Therapeutic currently has a consensus price target of $80.29, indicating a potential upside of 426.81%. Artiva Biotherapeutics has a consensus price target of $17.00, indicating a potential upside of 476.27%. Given Artiva Biotherapeutics' higher probable upside, analysts plainly believe Artiva Biotherapeutics is more favorable than Tectonic Therapeutic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tectonic Therapeutic 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88Artiva Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummaryTectonic Therapeutic beats Artiva Biotherapeutics on 9 of the 13 factors compared between the two stocks. Get Artiva Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARTV and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARTV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARTV vs. The Competition Export to ExcelMetricArtiva BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.07M$3.30B$6.10B$10.52BDividend YieldN/A2.29%5.68%4.68%P/E RatioN/A21.8677.4026.67Price / Sales288.27264.79517.33204.58Price / CashN/A46.3737.8961.26Price / Book0.389.9312.556.55Net Income-$65.37M-$52.59M$3.30B$277.34M7 Day Performance-0.34%5.28%28,056.17%2.41%1 Month Performance-7.23%12.54%28,977.34%9.26%1 Year Performance-80.84%28.76%35,796.37%32.66% Artiva Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARTVArtiva Biotherapeutics3.3262 of 5 stars$2.95flat$17.00+476.3%-81.2%$72.07M$250K0.0081TECXTectonic Therapeutic2.9588 of 5 stars$15.78+5.3%$80.29+408.8%-49.1%$280.31MN/A-3.91120LXEOLexeo Therapeutics3.0446 of 5 stars$5.31+3.1%$15.33+188.8%-23.2%$278.11M$650K-1.6358Positive NewsMREOMereo BioPharma Group2.6673 of 5 stars$1.85+6.3%$7.40+300.0%-52.2%$276.66M$10M-26.4340News CoveragePositive NewsABEOAbeona Therapeutics4.4171 of 5 stars$5.48+1.9%$19.50+255.8%-14.6%$275.88M$3.50M7.8390Insider TradeCADLCandel Therapeutics2.7359 of 5 stars$5.23+8.7%$20.00+282.4%-20.6%$264.05M$120K-7.5860DBVTDBV Technologies2.4826 of 5 stars$9.50flat$14.75+55.3%+271.3%$260.25M$4.15M-1.9980Positive NewsGap UpALLOAllogene Therapeutics2.9882 of 5 stars$1.17+0.9%$8.44+621.7%-49.0%$257.38M$20K-1.05310Positive NewsEDITEditas Medicine4.2685 of 5 stars$3.00+6.0%$5.10+70.0%+20.8%$254.47M$32.31M-1.05230Gap UpREPLReplimune Group4.7443 of 5 stars$3.27+1.6%$6.50+98.8%-62.1%$251.73MN/A-1.01210Positive NewsLYELLyell Immunopharma1.2792 of 5 stars$13.17+0.6%$15.00+13.9%-35.7%$251.48M$60K-0.54270High Trading Volume Related Companies and Tools Related Companies TECX Alternatives LXEO Alternatives MREO Alternatives ABEO Alternatives CADL Alternatives DBVT Alternatives ALLO Alternatives EDIT Alternatives REPL Alternatives LYEL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARTV) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredThe Fed Just Got Kneecapped — Here’s What Happens NextDonald Trump has done it again! This time, with the signing of the highly controversial new law S.1582 — he...Banyan Hill Publishing | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredChina’s message to TrumpPorter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artiva Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artiva Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
